#ASCO14 - Poster: ARN-509 in patients with metastatic castration-resistant prostate cancer with and without prior abiraterone acetate treatment

CHICAGO, IL USA (UroToday.com) - Presented by Dana E. Rathkopf,¹ Emmanuel S. Antonarakis,² Neal D. Shore,³ Ronald Tutrone,⁴ Joshi J. Alumkal,⁵ Charles J. Ryan,⁶ Mansoor N. Saleh,⁷ Ralph J. Hauke,⁸ Rajesh Bandekar,⁹ Edna Chow Maneval,¹⁰ Carla J. de Boer,¹¹ Mary B. Todd,¹² Margaret K. Yu,¹³ and Howard I. Scher¹ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY USA
²Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD USA
³Carolina Urologic Research Center, Myrtle Beach, SC USA
⁴Chesapeake Urologic Research Associates, Baltimore, MD USA
⁵Oregon Health and Science University, Knight Cancer Institute, Portland, OR USA
⁶University of California San Francisco, San Francisco, CA USA
⁷Georgia Cancer Specialists PC, Sandy Springs, GA USA
⁸Nebraska Cancer Specialists, Omaha, NE USA
⁹Janssen Research & Development, Philadelphia, PA USA
¹⁰Seragon Pharmaceuticals, San Diego, CA USA
¹¹Janssen Biologics, B. V., Leiden, The Netherlands
¹²Janssen Global Services, Raritan, NJ USA
¹³Janssen Research & Development, Los Angeles, CA